Eckardt Volker F, Hoischen Tom, Bernhard Gudrun
Department of Gastroenterology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany.
Eur J Gastroenterol Hepatol. 2008 Oct;20(10):956-60. doi: 10.1097/MEG.0b013e3282fbf5e5.
Patients with achalasia require repeated invasive therapies and may experience multiple complications. The objectives of this study were to determine the incidence of such complications, causes of death, and life expectancy in 253 patients.
Patients consisted of two groups: group A comprised 177 patients with newly diagnosed achalasia; group B consisted of 76 patients in whom the diagnosis had been established in external institutions. All patients regularly underwent structured interviews and were reinvestigated if changes in health status occurred. Survival rates were determined by Kaplan-Meier estimates and were compared with those of an average German population. Causes of death were determined from hospital records, information supplied by private physicians, and from death certificates.
Complete follow-up was obtained in 98.9% (group A) and in 100% (group B) of all patients. The observation period for group A ranged from 2 to 33 years and for group B from 2 to 26 years (disease duration: 4-68 years). The most frequent complications were reflux esophagitis (group A: 6.2%, group B: 19.7%) and megaesophagus (group A: 6.2%, group B: 21.0%). Thirty-six patients had died during follow-up. Five of these deaths were related to achalasia. In group A, the estimated 20-year survival rates in patients with achalasia [76% (95% confidence interval (CI): 66-85%)] did not significantly differ from those in controls 80% (95% CI: 71-89%). In group B, 25-year survival rates were also similar in patients [87% (95% CI: 78-97%)] and controls [86% (95% CI: 76-97%)].
Patients with achalasia experience a significant number of complications. Causes of death and life expectancy, however, do not differ from those of the average population.
贲门失弛缓症患者需要反复接受侵入性治疗,且可能会出现多种并发症。本研究的目的是确定253例患者中此类并发症的发生率、死因及预期寿命。
患者分为两组:A组包括177例新诊断为贲门失弛缓症的患者;B组由76例在外部机构确诊的患者组成。所有患者均定期接受结构化访谈,若健康状况发生变化则重新进行调查。生存率通过Kaplan-Meier估计法确定,并与德国普通人群的生存率进行比较。死因根据医院记录、私人医生提供的信息以及死亡证明来确定。
所有患者中,A组98.9%、B组100%获得了完整随访。A组的观察期为2至33年,B组为2至26年(病程:4至68年)。最常见的并发症是反流性食管炎(A组:6.2%,B组:19.7%)和巨食管(A组:6.2%,B组:21.0%)。36例患者在随访期间死亡。其中5例死亡与贲门失弛缓症有关。在A组中,贲门失弛缓症患者的估计20年生存率[76%(95%置信区间(CI):66 - 85%)]与对照组[80%(95% CI:71 - 89%)]无显著差异。在B组中,患者[87%(95% CI:78 - 97%)]和对照组[86%(95% CI:76 - 97%)]的25年生存率也相似。
贲门失弛缓症患者会出现大量并发症。然而,其死因和预期寿命与普通人群并无差异。